Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $64.5 million.

  • IDEAYA Biosciences' Total Current Liabilities rose 58.66% to $64.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.5 million, marking a year-over-year increase of 58.66%. This contributed to the annual value of $46.1 million for FY2024, which is 70.00% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Total Current Liabilities stood at $64.5 million for Q3 2025, which was up 16.57% from $55.3 million recorded in Q2 2025.
  • IDEAYA Biosciences' Total Current Liabilities' 5-year high stood at $64.5 million during Q3 2025, with a 5-year trough of $24.9 million in Q3 2023.
  • Its 3-year average for Total Current Liabilities is $39.1 million, with a median of $40.7 million in 2024.
  • As far as peak fluctuations go, IDEAYA Biosciences' Total Current Liabilities soared by 391.82% in 2021, and later plummeted by 56.38% in 2023.
  • IDEAYA Biosciences' Total Current Liabilities (Quarterly) stood at $45.2 million in 2021, then declined by 29.76% to $31.7 million in 2022, then decreased by 14.56% to $27.1 million in 2023, then skyrocketed by 70.00% to $46.1 million in 2024, then skyrocketed by 58.66% to $64.5 million in 2025.
  • Its Total Current Liabilities was $64.5 million in Q3 2025, compared to $55.3 million in Q2 2025 and $50.8 million in Q1 2025.